The FDA announced today that it approved Enhertu, an IV infusion for the treatment of patients with unresectable or metastatic HER2-low breast cancer. Enhertu (fam-trastuzumab-deruxtecan-nxki) IV infusion is now the first approved therapy targeted to patients with the HER2-low breast cancer subtype, which is a newly defined subset of HER2-negative breast cancer. The therapy received […]
